NCT02300701View on ClinicalTrials.gov

Role of Anti-IgE in Severe Childhood Eczema

PHASE4CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

August 31, 2018

Study Completion Date

August 31, 2018

Conditions
Atopic EczemaAtopic DermatitisChild
Interventions
DRUG

Xolair

According to manufacturer's instructions

DRUG

Placebo

Placebo

Trial Locations (1)

SE1 7EH

Guy's and St Thomas' NHS Foundation Trust, London

All Listed Sponsors
collaborator

King's College London

OTHER

collaborator

National Institute for Health Research, United Kingdom

OTHER_GOV

lead

Guy's and St Thomas' NHS Foundation Trust

OTHER

NCT02300701 - Role of Anti-IgE in Severe Childhood Eczema | Biotech Hunter | Biotech Hunter